SCHEMBL5963839

SCHEMBL5963839

O=Cc1ccc(-c2ccccc2C(F)(F)F)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.43
CYP3A4 P08684 4/20 0.41
CYP1A2 P05177 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
OXTR P30559 2/20 0.40
AVPR1A P37288 2/20 0.40
CYP2D6 P10635 3/20 0.40
CYP2C19 P33261 3/20 0.40
TSHR P16473 2/20 0.40
HIF1A Q16665 1/20 0.40
KDM1A O60341 1/20 0.39
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
METAP2 P50579 1/20 0.39
ATR Q13535 1/20 0.39
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913181 0.79 NPC1 (0.49) ALDH1A1L3MBTL1ALOX5APFEN1
SCHEMBL2406803 0.76 ALOX5AP (0.48) KMOCYP3A4CYP1A2ALDH1A1CYP2D6
SCHEMBL2004558 0.76 IDO1 (0.42) CYP3A4CYP1A2ALDH1A1KDM4EOXTR
SCHEMBL8304819 0.76 CCR1 (0.50) KMOCYP3A4CYP1A2ALDH1A1CYP2D6
SCHEMBL6018826 0.76 CYP11B1 (0.47) ALDH1A1KDM4EL3MBTL1KDM1AALOX5AP
SCHEMBL15060623 0.75 CYP3A4 (0.44) KMOCYP3A4CYP1A2ALDH1A1KDM4E
SCHEMBL8305847 0.75 KMO (0.43) KMOCYP3A4CYP1A2ALDH1A1OXTR
SCHEMBL566340 0.75 KIF11 (0.53) ALDH1A1KDM4EHSD11B1
SCHEMBL15333189 0.75 ATR (0.42) KMOCYP3A4CYP1A2ALDH1A1KDM4E
SCHEMBL8303037 0.74 LDHA (0.57) KMOALDH1A1L3MBTL1OXTRAVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110386881-B Diarylethene compound, pharmaceutical composition and application thereof 中国科学院昆明植物研究所 2021-03-02 CN disclosed
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain ASTRAZENECA AB (SE) 2006-03-09 US disclosed
EP-1594856-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN AstraZeneca AB (SE) 2005-11-16 EP disclosed
WO-2004060882-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain CNR1, CNR2, OPRL1 KMO 3324/4885CYP3A4 887/4885CYP1A2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.